CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Etoposide +1 moredrug
Likely dose
Etoposide 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00693719
NCT00693719Phase 2Completed
CompareCT.gov

A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer

University of Arizona·interventional·Posted Jun 9, 2008·Updated Nov 20, 2015

In Brief

A Phase 2 clinical trial evaluating Etoposide and Irinotecan hydrochloride for Breast Cancer. Completed, enrolled 31 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with etoposide works in treating patients with recurrent, locally advanced, or metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 9, 2008
Enrollment StartAug 1, 2007
Primary CompletionDec 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.1 years ago

Interventions

Etoposidedrug

50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle

Irinotecan hydrochloridedrug

Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle